Screening for Mycobacterium tuberculosis infection in risk groups, diagnosis of active disease, and planning of long-term combination antibiotic therapy.
Indication
- Cough lasting more than two weeks, blood-streaked sputum, night sweats, and weight loss
- Close contact with a patient with active tuberculosis
- High-risk conditions such as HIV, chronic kidney failure, cancer, and immunosuppressive therapy
- Screening of healthcare workers, prison staff, and migrant populations
- Latent infection assessment before anti-TNF therapy
- Evaluation of contact risk in children after BCG vaccination
Preparation
- Detailed history, physical examination, and risk assessment
- Tuberculin skin test (PPD) or interferon-gamma release assay (IGRA)
- Chest X-ray and, if needed, thorax computed tomography
- AFB and TB-PCR with culture and antibiogram on three separate morning sputum samples
- Liver function tests and baseline vision/hearing assessment
How it's performed
- In screen-positive but asymptomatic patients, latent TB therapy is planned (commonly 9 months of isoniazid or 3 months of rifapentine-isoniazid)
- In patients diagnosed with active TB, an initial 2-month intensive phase: isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE)
- A 4-7 month continuation phase with isoniazid and rifampicin; total treatment 6-9 months
- Adherence is monitored using directly observed therapy (DOT)
- In multidrug-resistant (MDR-TB) cases, treatment may be extended to 18-24 months and require different combinations
- Contacts are screened and preventive treatment is started for those who need it
Post-procedure
- Monthly clinical follow-up, sputum monitoring, and liver function testing
- Report side effects such as visual problems (ethambutol) or numbness (isoniazid) to the physician
- Avoid smoking, alcohol, and drugs harmful to the liver during treatment
- Clinical and radiological cure assessment at the end of therapy
- Public health notification and follow-up of contacts
Risks
- Drug-induced liver toxicity (especially with isoniazid and rifampicin)
- Changes in visual fields (ethambutol) and decreased visual acuity
- Peripheral neuropathy due to isoniazid (vitamin B6 supplementation reduces the risk)
- Allergic rashes and joint pain (pyrazinamide)
- Development of resistant (MDR/XDR) tuberculosis with poor adherence
FAQ
Will my PPD be positive if I had a BCG vaccine?
Some individuals can have temporary positivity after vaccination; in uncertain cases, the IGRA test is preferred.
Can I continue working during treatment?
Once sputum smears become negative (usually within the first 2-3 weeks), infectiousness is greatly reduced; you can return to work with your physician's approval.
What happens if I stop the medication early?
Stopping early increases the risk of relapse and the development of resistant (MDR) tuberculosis; full adherence to the treatment plan is very important.
Can tuberculosis be fully cured?
With appropriate, full-course treatment, the great majority of patients recover; however, no guarantee of complete cure can be made without ongoing physician follow-up.
Related Information
Related Medical Services
Other services in the same specialty or with similar indications you may want to explore.
Bronchoscopy
Pulmonology
Direct visualization of the airways and sampling using a thin camera-equipped instrument.
Pneumonia Treatment
Pulmonology
Pneumonia treatment — management of bacterial, viral, or fungal lung infection.
Bronchiectasis — Diagnosis, Treatment, and Follow-up
Pulmonology
Bronchiectasis diagnosis and treatment process — evaluation and management of permanent dilation of the airways.
Spirometry
Pulmonology
A core test that measures the breathing capacity of the lungs and distinguishes obstructive from restrictive diseases.
Pulmonary Function Tests
Pulmonology
Comprehensive evaluation of lung volumes, flows, and gas exchange with PFT.
COPD Evaluation and Treatment
Pulmonology
Diagnosis, classification and individualized management of COPD according to GOLD guidelines.
Asthma Evaluation and Treatment
Pulmonology
Asthma diagnosis, control assessment, and stepwise treatment management based on the GINA guidelines.
Lung Cancer Screening
Pulmonology
Lung cancer screening — early detection program with low-dose CT in high-risk individuals.